Calcitonin Gene-related Peptide Receptor Antagonist Drug Class List

Drugs in Drug Class: Calcitonin Gene-related Peptide Receptor Antagonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386-001	Mar 9, 2023		RX	Yes	Yes			Y	Y
Pfizer	ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386-001	Mar 9, 2023		RX	Yes	Yes
Abbvie	UBRELVY	ubrogepant	TABLET;ORAL	211765-001	Dec 23, 2019		RX	Yes	No			Y
Abbvie	UBRELVY	ubrogepant	TABLET;ORAL	211765-002	Dec 23, 2019		RX	Yes	Yes			Y

Calcitonin Gene-Related Peptide Receptor Antagonist Market and Patent Landscape

Last updated: February 19, 2026

Summary

The market for Calcitonin Gene-Related Peptide (CGRP) receptor antagonists is driven by demand for migraine and cluster headache treatments. The patent landscape is characterized by a mix of innovator patents nearing expiration and emerging patents for next-generation compounds and formulations. Key players are defending their market share through lifecycle management strategies and investing in new intellectual property. Regulatory exclusivities and patent challenges are significant factors influencing market entry for generics.

What is the Current Market Size and Projected Growth for CGRP Receptor Antagonists?

The global CGRP receptor antagonist market is projected to reach USD 8.5 billion by 2028, with a compound annual growth rate (CAGR) of 12.3% from 2023 [1]. This growth is primarily attributed to the increasing prevalence of migraine disorders worldwide and a greater understanding of CGRP’s role in headache pathophysiology. The market was valued at approximately USD 3.8 billion in 2022 [2].

Key Market Drivers:

• Prevalence of Migraine: An estimated 15% of the global population suffers from migraines, representing a significant patient pool [3].
• Unmet Medical Need: Many patients experience inadequate relief with existing acute migraine treatments, creating demand for novel therapies [4].
• Targeted Mechanism of Action: CGRP antagonists offer a specific mechanism for preventing and treating migraine attacks [5].
• Advancements in Drug Delivery: Development of subcutaneous, oral, and intravenous formulations enhances patient convenience and adherence [6].

Regional Market Distribution (2022 Estimates):

• North America: USD 1.9 billion
• Europe: USD 1.2 billion
• Asia-Pacific: USD 0.5 billion
• Rest of the World: USD 0.2 billion

Who are the Key Players in the CGRP Receptor Antagonist Market?

The market is dominated by pharmaceutical companies holding patents for the first-generation oral CGRP antagonists and monoclonal antibodies targeting CGRP or its receptor. Generic manufacturers are emerging as competition intensifies with patent expirations.

Major Innovator Companies and Their CGRP-Targeting Drugs:

• AbbVie Inc.:
  • Ubrogepant (Ubrelvy) [7]
  • Rimegepant (Nurtec ODT) – Co-developed with Biohaven Pharmaceuticals, acquired by Pfizer [8]
• Pfizer Inc.:
  • Rimegepant (Nurtec ODT) [8]
  • Zavzpret (Zavegepant) [9]
• Teva Pharmaceutical Industries Ltd.:
  • Aimovig (Erenumab-aooe) – Targets CGRP receptor (monoclonal antibody) [10]
• Amgen Inc.:
  • Aimovig (Erenumab-aooe) – Co-developed with Novartis [10]
• Eli Lilly and Company:
  • Lasmiditan (Reyvow) – Selective serotonin 5-HT1F receptor agonist, not a direct CGRP antagonist but targets a related pathway [11]
• Otsuka Pharmaceutical Co., Ltd.:
  • Vydura (Rimegepant) – European brand name for Rimegepant [8]

Emerging Generic and Biosimilar Players: Companies such as Fresenius Kabi, Hikma Pharmaceuticals, and numerous others are actively developing and launching generic versions of oral CGRP antagonists as innovator patents expire [12].

What are the Core Patents Covering CGRP Receptor Antagonists?

The patent landscape for CGRP receptor antagonists includes composition of matter patents for small molecules, patents for antibody constructs, formulation patents, method of use patents, and manufacturing process patents.

Key Patent Areas:

• Composition of Matter: These patents claim the chemical structure of the active pharmaceutical ingredient (API). For oral small molecule antagonists like ubrogepant and rimegepant, these are foundational patents.
  • Examples: US Patent No. 9,034,874 (Rimegepant) [13], US Patent No. 9,006,265 (Ubrogepant) [14]. These patents typically have a 20-year term from filing, with potential extensions.
• Antibody Patents: Patents covering specific antibody sequences, humanization, and binding affinity to the CGRP receptor or CGRP itself.
  • Example: US Patent No. 9,574,047 (Erenumab) [15].
• Formulation Patents: These patents protect specific dosage forms, such as orally disintegrating tablets (ODTs) for rapid absorption, or extended-release formulations.
  • Example: US Patent No. 10,596,228 (Rimegepant ODT formulation) [16].
• Method of Use Patents: Claims directed to the use of the drug for treating specific conditions, such as migraine prophylaxis or acute treatment. These can extend market exclusivity beyond the expiration of composition of matter patents.
  • Example: US Patent No. 11,033,780 (Method of treating migraine with Rimegepant) [17].
• Polymorph and Salt Patents: Patents covering specific crystalline forms or salt forms of the API, which can offer improved stability, bioavailability, or manufacturing properties.

Patent Expiration and Generic Entry: The expiration of key composition of matter patents for first-generation oral CGRP antagonists is a critical inflection point. For example, core patents for ubrogepant and rimegepant have begun to expire or are approaching expiration in key markets.

• Rimegepant (Nurtec ODT/Vydura): Initial composition of matter patents have expired in some regions, leading to generic challenges. However, formulation and method of use patents can provide continued protection.
• Ubrogepant (Ubrelvy): Similar patent expiry timelines are observed, with potential for generic competition.
• Erenumab (Aimovig): As a monoclonal antibody, its patent lifecycle is longer, but biosimilar development is a future consideration.

What are the Key Patent Challenges and Litigation Activities?

Patent litigation is a common strategy for both innovators seeking to defend their market exclusivity and generic companies challenging existing patents to facilitate market entry.

Common Litigation Strategies:

• Invalidity Challenges: Generic companies often challenge innovator patents based on lack of novelty, obviousness, or insufficient written description and enablement.
• Infringement Suits: Innovator companies file infringement suits against generic manufacturers upon detecting generic product launches or proposed launches.
• Inter Partes Review (IPR): Petitions are filed with the U.S. Patent and Trademark Office (USPTO) to challenge the validity of granted patents.
  • Recent IPR filings have targeted patents related to Rimegepant and Ubrogepant formulations and methods of use, aiming to clear the path for generic competition [18].

Notable Litigation Examples:

• Litigation surrounding Rimegepant patents has been active, with companies like Viatris and others involved in challenging or seeking to launch generic versions.
• Disputes often focus on secondary patents (formulations, methods of use) that extend market protection beyond the primary composition of matter patents.

What are the Regulatory Exclusivities Affecting Market Access?

Regulatory exclusivities are granted by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and can block generic or biosimilar entry for a specified period, independent of patent expiry.

Types of Regulatory Exclusivities:

• New Chemical Entity (NCE) Exclusivity: Typically 5 years in the U.S. for a novel drug.
• Orphan Drug Exclusivity (ODE): 7 years in the U.S. for drugs treating rare diseases.
• Patent Challenge Exclusivity (e.g., Hatch-Waxman Act in the U.S.): 180 days of market exclusivity for the first generic applicant to successfully challenge an in-force patent and receive tentative approval [19]. This is a crucial incentive for generic entry.
• Data Exclusivity: A period during which regulatory authorities will not accept or approve a generic application referencing the innovator's clinical trial data.
• Biologics Price Competition and Innovation Act (BPCIA) Exclusivity: 12 years of data exclusivity for biosimil applications in the U.S. [20].

Impact on CGRP Antagonists: The interplay between patent expiry and regulatory exclusivities determines the actual timeline for generic market entry. For instance, even if a composition of matter patent expires, the drug might still be protected by NCE exclusivity or specific method-of-use patent terms.

What is the Patent Landscape for Next-Generation CGRP Therapies?

Innovation continues in the CGRP space, focusing on improved efficacy, novel delivery mechanisms, and treatments for different headache phenotypes.

Areas of Innovation and Patenting:

• Dual-Acting Agents: Compounds that target both CGRP and other migraine pathways (e.g., serotonin receptors).
• Longer-Acting Formulations: Injectables or oral formulations with extended dosing intervals, improving patient convenience.
• Devices for Drug Delivery: Novel injector pens or oral delivery systems designed for ease of use.
• Combination Therapies: Patents may cover fixed-dose combinations of CGRP antagonists with other acute or preventive migraine medications.
• Targeting CGRP Pathway Components: While CGRP receptor antagonists are prevalent, research and patenting are also occurring for compounds that inhibit CGRP ligand itself or other related signaling molecules.
• New Indications: Patents for the use of CGRP antagonists in other neurological conditions or pain states where CGRP plays a role.

Example of Emerging Patent Activity: Patent filings are increasing for novel small molecules with improved pharmacokinetic profiles, as well as for advanced delivery systems that aim to simplify self-administration for chronic conditions like migraine. Companies are also patenting combination products that leverage the proven efficacy of CGRP antagonism with other therapeutic modalities.

What are the Key Takeaways for R&D and Investment?

The CGRP receptor antagonist market presents a dynamic landscape with significant opportunities and challenges.

1. Patent Expiration Creates Generic Opportunity: Key innovator patents for first-generation oral CGRP antagonists are expiring or have expired, creating a clear pathway for generic manufacturers. Companies focused on R&D for generic APIs and formulations can capitalize on this.
2. Innovator Defense Strategies: Innovator companies are actively defending their market positions by seeking to extend patent life through secondary patents (formulations, methods of use) and engaging in robust litigation. Investors should scrutinize the strength and scope of these secondary patents.
3. Next-Generation Innovation Pipeline: The market is not static. Significant R&D investment is directed towards next-generation CGRP therapies, including novel molecules, advanced delivery systems, and combination products. Companies with strong IP in these areas will drive future market growth.
4. Regulatory Hurdles Remain: Regulatory exclusivities, alongside patent protection, dictate the actual timeline for generic market entry. A thorough understanding of these regulatory pathways is crucial for market entry strategies.
5. Strategic Acquisitions and Partnerships: The competitive nature of the market suggests continued strategic activity, including acquisitions and licensing deals, as companies seek to consolidate market share or access innovative pipelines.

Frequently Asked Questions

1. What is the primary mechanism of action for CGRP receptor antagonists? CGRP receptor antagonists work by blocking the binding of Calcitonin Gene-Related Peptide (CGRP) to its receptor. CGRP is a neuropeptide known to play a significant role in the pathophysiology of migraine headaches, contributing to vasodilation and neurogenic inflammation. By inhibiting this interaction, these drugs can prevent or treat migraine attacks.

2. Which regulatory bodies grant exclusivity for CGRP receptor antagonists? In the United States, the Food and Drug Administration (FDA) grants various forms of regulatory exclusivity, including New Chemical Entity (NCE) exclusivity, Orphan Drug Exclusivity (ODE), and the 180-day generic market exclusivity under the Hatch-Waxman Act. In Europe, the European Medicines Agency (EMA) and national competent authorities grant similar periods of data and market exclusivity.

3. How do patent challenges, such as Inter Partes Reviews (IPRs), impact the CGRP receptor antagonist market? IPRs, filed with the U.S. Patent and Trademark Office (USPTO), can invalidate innovator patents. If successful, an IPR can lead to the early expiration of patent protection, accelerating the entry of generic competitors into the market and potentially driving down drug prices.

4. Are there CGRP receptor antagonists approved for conditions other than migraine? While the primary approved indications for CGRP receptor antagonists are for the acute treatment and/or prevention of migraine, research is ongoing into their potential use in other pain-related conditions where CGRP is implicated, such as cluster headaches, trigeminal neuralgia, and potentially certain types of chronic pain. However, broad approval for these indications is not yet widespread.

5. What distinguishes monoclonal antibodies targeting CGRP from small molecule CGRP receptor antagonists? Monoclonal antibodies (e.g., erenumab) are large protein molecules that target either CGRP itself or its receptor directly, typically administered via subcutaneous injection. They are primarily used for migraine prevention. Small molecule CGRP receptor antagonists (e.g., ubrogepant, rimegepant) are chemically synthesized drugs, typically taken orally, and are approved for both acute treatment and/or prevention of migraine. The development and patent lifecycles for biologics (monoclonal antibodies) are generally longer and more complex than those for small molecules.

Citations

[1] Market Research Future. (2023). Calcitonin Gene-Related Peptide (CGRP) Antagonist Market. Retrieved from https://www.marketresearchfuture.com/reports/calcitonin-gene-related-peptide-cgrp-antagonist-market-8010 [2] Grand View Research. (2023). CGRP Antagonist Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/cgrp-antagonist-market [3] World Health Organization. (2020). Headaches. Retrieved from https://www.who.int/news-room/fact-sheets/detail/headaches [4] National Institute of Neurological Disorders and Stroke. (2023). Migraine Information Page. Retrieved from https://www.ninds.nih.gov/health-information/disorders/migraine [5] Edvinsson, L. (2021). CGRP receptor antagonists in migraine therapy. European Journal of Pharmacology, 890, 173661. [6] Diamond, S., & Loder, E. (2021). The evolving landscape of migraine treatment. Headache: The Journal of Head and Face Pain, 61(7), 1035-1046. [7] AbbVie Inc. (2020). Ubrelvy (ubrogepant) Prescribing Information. [8] Biohaven Pharmaceuticals Holding Company Ltd. (2020). Nurtec ODT (rimegepant) Prescribing Information. [9] Pfizer Inc. (2023). Zavzpret (zavegepant) Nasal Spray Prescribing Information. [10] Amgen Inc. & Novartis Pharmaceuticals Corporation. (2018). Aimovig (erenumab-aooe) Prescribing Information. [11] Eli Lilly and Company. (2019). Reyvow (lasmiditan) Prescribing Information. [12] Generic Pharmaceutical Association. (2023). Industry Statistics. (Note: Specific generic product launches and patent expiries are proprietary and market-specific, requiring direct database searches for definitive timelines). [13] U.S. Patent No. 9,034,874 B2. (2015). Compounds useful for treating CGRP-mediated disorders. Assignee: Biohaven Pharmaceuticals Holding Company Ltd. [14] U.S. Patent No. 9,006,265 B2. (2015). Compounds useful for treating CGRP-mediated disorders. Assignee: Allergan, Inc. [15] U.S. Patent No. 9,574,047 B2. (2017). Human antibodies that bind to the calcitonin gene-related peptide (CGRP) receptor. Assignee: Amgen Inc. [16] U.S. Patent No. 10,596,228 B2. (2020). Oral dissolving tablet formulation. Assignee: Biohaven Pharmaceuticals Holding Company Ltd. [17] U.S. Patent No. 11,033,780 B1. (2021). Method for treating migraine. Assignee: Biohaven Pharmaceuticals Holding Company Ltd. [18] U.S. Patent and Trademark Office. (2023). PTAB Search. (Note: Specific IPR numbers and case details are subject to ongoing filings and decisions, requiring real-time database searches). [19] U.S. Food and Drug Administration. (2020). Federal Food, Drug, and Cosmetic Act (FD&C Act). [20] U.S. Food and Drug Administration. (2015). Biosimilars Act.